Printer Friendly

GENETICS INSTITUTE PLANS $55 MILLION FACILITY EXPANSION IN MASSACHUSETTS

GENETICS INSTITUTE PLANS $55 MILLION FACILITY EXPANSION IN MASSACHUSETTS
 CAMBRIDGE, Mass., Sept.16 /PRNewswire/ -- Genetics Institute, Inc. (NASDAQ: GENIZ)announced today that it is moving ahead with a significant expansion of its existing 210,000 square foot product development and manufacturing site in Andover, Mass. The new $55 million Andover expansion project includes: a 113,000 square-foot preclinical research and development building; a 42,000 square foot central energy plant; and site preparation for potential future expansion on the 53 acre Genetics Institute Andover campus.
 "When complete, this expansion project will provide us with space for approximately 200 additional employees in Andover and will bring our total investment in facilities in Andover to over $130 million," said Gabriel Schmergel, President and Chief Executive Officer of Genetics Institute.
 "Genetics Institute's expansion in Andover means more new jobs for Massachusetts, and represents a key vote of confidence for the Commonwealth by one of the leading companies in the biotechnology industry," said Massachusetts Secretary of Economic Affairs, Stephen P. Tocco. "Genetics Institute's expansion plans illustrate the growth of a successful Massachusetts-grown company and highlight the potential benefits of the economic incentives embodied in the new economic development plan announced by Governor Weld today."
 Genetics Institute, the largest biotechnology company employer in Massachusetts, is close to meeting its target of hiring over 100 new employees in 1992, bringing its full-time employee base to over 700. Approximately half of these employees currently work in Andover and the other half work in the Company's 145,000 square foot corporate headquarters and discovery research facilities in Cambridge, Mass. In August, Genetics Institute also announced that it purchased an additional 43,000 square foot research facility in Cambridge to provide for its expanding Small Molecule Drug Discovery program.
 "While Andover was our preferred site for this major expansion program, we considered other alternatives both within and outside of Massachusetts," said Garen Bohlin, Executive Vice President of the Company. "In the end, we were able to work successfully with highly responsive officials from the Commonwealth of Massachusetts and the Town of Andover to meet our needs in Andover."
 The architects and engineers for the Andover expansion project include Payette Associates, BR&A /Sullivan Partnership and McNamara/Salvia, all of Boston, Martinage Engineering Associates of Reading, and Sasaki Associates of Watertown.
 Genetics Institute (NASDAQ: GENIZ) is a leading biopharmaceutical firm engaged in the discovery and development of human pharmaceuticals through recombinant DNA and other technologies. The Company is developing three human pharmaceuticals which it hopes to commercialize in the U.S. in the mid-1990's. These products are now being tested for their potential use in treating serious bone fractures, cancer, the side effects of chemotherapy and infectious disease. The Company's early product discoveries are being developed and commercialized by marketing partners. Recormon(R)and Epogin(R) brands of EPO are on the market in Europe and Japan. Leucomax(tm) brand GM-CSF was recommended for approval last week in the European Community and awaits U.S. marketing approval. Recombinate(tm) brand Factor VIII antihemophilic factor awaits marketing approvals in the U.S. and Europe.
 -0- 9/16/92
 /CONTACT: Melinda Lindquist or Gina Price of Genetics Institute (617) 876-1170/
 (GENIZ) CO: Genetics Institute, Inc. ST: Massachusetts IN: MTC SU:


CH -- NE004 -- 9949 09/16/92 08:53 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 16, 1992
Words:547
Previous Article:CORESTATES TO ACQUIRE FINANCIAL TELESIS, INC., LOCKBOX PROCESSING AND DATA MANAGEMENT FIRM
Next Article:HEALTHINFUSION ANNOUNCES SIGNING OF MERGER AGREEMENT WITH NAPLES HOME MEDICAL SERVICES
Topics:


Related Articles
JACOBS RESIGNS FROM GENETICS INSTITUTE BOARD OF DIRECTORS
GENETICS INSTITUTE AND SCIGENICS PLAN TO FILE AMENDED PROTOCOL FOR TESTING OF M-CSF AS CHOLESTEROL LOWERING AGENT
GENETICS INSTITUTE AND SCIGENICS PLAN TO FILE AMENDED PROTOCOL FOR TESTING OF M-CSF AS CHOLESTEROL LOWERING AGENT
CAMBRIDGE BIOTECH CORPORATION TO BUILD MANUFACTURING FACILITY IN MASSACHUSETTS
GENETICS INSTITUTE - YAMANOUCHI JOINT VENTURE TO MARKET rhIL-11 IN JAPAN
GENETICS INSTITUTE AND SCIGENICS RECEIVE FDA GO AHEAD ON M-CSF CHOLESTEROL STUDY
TARGETED GENETICS OPENS NEW RESEARCH AND ADMINISTRATION FACILITY
GENETICS INSTITUTE ANNOUNCES OUTCOME OF CONVERTIBLE EXCHANGEABLE PREFERRED STOCK REDEMPTION
PATRICK GAGE, PH.D. TO BECOME GENETICS INSTITUTE'S CHIEF OPERATING OFFICER; OTHER OFFICERS APPOINTED
GENENTECH PATENT WILL HAVE NO IMPACT ON GENETICS INSTITUTE

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters